• Andrew Zinn.
• Department of Plastic Surgery, New York University School of Medicine, New York, NY, USA. jacobj15@nyumc.org
• Crit. Care Med.. 2012 Jan 1;40(1):285-9.

ObjectiveThe development of drug-eluting stents has decreased the rate of in-stent restenosis. However, there have been reports of late stent thrombosis in patients with drug-eluting stents, especially when dual antiplatelet therapy is interrupted. The high mortality rate associated with cardiac stent thrombosis has led to recent recommendations regarding duration of antiplatelet therapy as well as timing of elective surgery in patients with both drug-eluting stents and bare metal stents. However, in patients requiring emergency operations, delaying surgery is not an option.Data SourcesIn a retrospective review of 65 patients undergoing replantation from 2005 to 2010, only two patients with coronary stents presented, both with drug-eluting stents. Both of these patients developed acute in-stent thrombosis postoperatively (days 5 and 2) despite continuing dual antiplatelet therapy while undergoing multidigit replantation.ConclusionsSeveral factors including large transfusion requirements and the complex pharmacogenetics of clopidogrel may have played a role. These cases bring to light the increasing number of patients with indwelling drug-eluting stents in whom the need for massive surgical or trauma type management will become more frequent.

21 keywords...

hide…